Search

Your search for "anpc" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receive First Payment on ‘Milestone’ Purchase of Cancer Detection Equipment

March 7, 2023

AnPac Bio-Medical Science (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection, received the first payment in late February 2023 from a Malaysian customer that had purchased AnPac Bio’s Model AP9080 cancer detection devices. The contract for these devices totaled $1.5 million. According to the announcement, the proprietary Model AP9080 features […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces US$5M Private Placement

March 6, 2023

AnPac Bio (NASDAQ: ANPC) is a company with operations in the United States and China focused on early cancer screening and detection with plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian-sourced food products. The company today announced its entry into definitive investment agreements with certain […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Reports Positive Results from Multiyear, Multicancer Follow-Up Study

February 22, 2023

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection and with plans to enter into the operation of a business-to-business (“B2B”) e-commerce food platform focused on the sale of Asian-sourced food products, is releasing information on the results of a major follow-up […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Acquires GISN to Enhance Efficiency of e-Commerce Operations

February 15, 2023

AnPac Bio (NASDAQ: ANPC), a company with operations in the United States and China, is engaged in early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian-sourced food products. The company today announced the closing of the acquisition of GISN (HK) […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Inks Acquisition Deal to Expand in the US

February 13, 2023

AnPac Bio-Medical Science (NASDAQ: ANPC), a company with operations in the United States and China, and its subsidiary Foodbase Group Inc, have signed a definitive equity purchase agreement; the agreement outlines the acquisition of a group of affiliated companies: SLV Windfall Group LLC, Windfall SLV Development LLC and SLV Windfall Management LLC. These companies are engaged in developing, […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Signs Agreement to Acquire a B2B Asian Food E-Commerce Platform

February 9, 2023

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection and with plans to enter into the operation of a business-to-business (“B2B”) e-commerce food platform focused on the sale of Asian-sourced food products, has signed a definitive agreement to acquire Fresh2 Ecommerce Inc. […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Signs $5.2M of Definitive Investment Agreements

January 25, 2023

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection and a business-to-business (“B2B”) food e-commerce company, announced that in December 2022 and January 2023, the company signed definitive agreements with several third party investors. According to the update, the investors agreed to […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Report Noting 48.8% Decrease in 2022 Net Loss

December 20, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, is reporting its unaudited financial results for the six months ended June 30, 2022. Highlights of the report for the first half of 2022 include total revenue of an estimated $778,000, a decrease of 43.7% compared to the same period […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces $5M Private Placement, Formation of Fresh2 Technology Inc.

December 5, 2022

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, today announced that it has reached a mutual understanding with nine investors. Through a private placement, the investors will subscribe for and purchase from the company a total of 28,571,428 newly issued Class […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Regains Compliance with Nasdaq Listing Requirement

November 30, 2022

AnPac Bio (NASDAQ: ANPC) is a biotechnology company with operations in the United States and China focused on early cancer screening and detection. The company today announced that it has been notified by the Office of the General Counsel of The Nasdaq Stock Market LLC that it has regained compliance with the minimum $1 per […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Board of Directors Sees Changes

November 10, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, is announcing changes to its board of directors and management team. According to the announcement, both Yuyang Cui and Jiawen Kang have resigned. Cui was serving as cochair of the board and […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Continued Listing Status Granted by NASDAQ Hearing Panel

November 4, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, is able to continue to list its shares on the NASDAQ Capital Market. The company received the notification from Nasdaq Hearings Panel of the Listing Qualifications Department of the Nasdaq Stock Market […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Plans to Implement ADS Ratio Change

October 18, 2022

AnPac Bio (NASDAQ: ANPC) is a biotechnology company with operations in the United States and China focused on early cancer screening and detection. The company today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its Class A ordinary shares from one (1) ADS representing one (1) Class A […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names New Board Members, Management Changes

October 4, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, has made changes in its board membership and on its management team. The company announced that Haohan Xu has been appointed as a director of the board of directors (the “Board”); he […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC), New Investor Group Sign $3.67M Equity Investment Agreements

September 27, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, has entered into legally binding investment agreements with nine institutional and individual investors; the agreements outline an investment in the company of approximately $3.67 million. According to the announcement, the various shares purchase […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces NASDAQ Delisting Appeal, Hearing

September 19, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, has filed a request with the NASDAQ Hearings Panel to appeal its delisting. The appeal, which was filed on Sept. 16, 2022, requests a hearing so that the company can present its […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names New Board Members, Co-CEO

August 8, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, has appointed a new board member as well as a new board chair and co-CEO. ANPC board of directors announced that Jiawen Kang will be serving as a member of the board […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Announcement Regarding Changes in Directors, Officers and Committees

July 19, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, has announced changes in the company’s directors and officers. The announcement stated that, on July 14, 2022, the company’s member approved written resolutions of a majority of the members. The resolutions addressed […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Regains Compliance to Remain Listed on Nasdaq Capital Market

June 10, 2022

AnPac Bio (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection, today announced that The Nasdaq Stock Market LLC has determined that it has regained compliance with the requirements to remain listed on The Nasdaq Capital Market, as required by a hearing panel’s decision dated May 4, 2022, subject to a one-year […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Financial Report for FY 2021

June 1, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, is reporting its financial results for the first quarter of fiscal year 2022, or the period ended March 31, 2022. The numbers are unaudited and have not yet been reviewed by the […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Financial Report for FY 2021

May 17, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, is reporting its annual financial results for the year ended December 31, 2021. Highlights of the report include total revenues of $2.8 million, down 12.3% from $3.1 million in fiscal year 2020, along with […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Regains Compliance with MVPHS Requirement

May 11, 2022

AnPac Bio (NASDAQ: ANPC) is a biotechnology company with operations in the United States and China focused on early cancer screening and detection. The company today announced its receipt of notification from the Nasdaq Stock Market LLC that ANPC’s American Depositary Shares are now in compliance with the maintenance of the minimum market value of […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receives Nasdaq Approval to Transfer Markets

May 6, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, announced that its request to transfer its American Depositary Shares from the Nasdaq Global Market to the Nasdaq Capital Market has been approved. The company anticipates continuing to list on the Nasdaq […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces New Appointments, Enters New Investment Agreement

April 11, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, has named a new CEO. Dr. Ai-dong Chen will be taking over the helm, replacing Dr. Chris Yu, AnPac founder, who resigned as board director, CEO and board chair. Chen was also […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Subsidiary Appraised, Approved to Explore Strategic Alternatives

March 3, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC) subsidiary Changwei System Technology (Shanghai) Co. Ltd. has been evaluated and appraised by China Alliance Appraisal (Shanghai) Co. Ltd. One of the top 10 appraisers in China by revenue, China Alliance is certified and licensed by the China Appraisal Society under the Ministry of Finance. Fully owned by AnPac Bio, […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for Breakthrough Medical Device Designation with FDA

February 3, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, has filed for a breakthrough device designation request for its cancer differentiation analysis (“CDA”) technology-based medical device; the company filed the request with the Food and Drug Administration (“FDA”) earlier this week. […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Ranked No. 1 Globally in Multi-Cancer Screening and Detection Test Volume

January 25, 2022

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that Frost & Sullivan Company, a leading and well-known U.S. market analysis and research firm, has ranked AnPac Bio globally as number one in worldwide multiple cancer screening and detection volume in a recent research report. Based on […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Proprietary Medical Device Passes Registration Tests, Slated to Start Clinical Trial

January 4, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a U.S.- and China-based biotechnology company focused on early cancer screening and detection, announced that its Class III medical device for lung cancer auxiliary diagnosis has passed stringent and rigorous registration tests; the tests were conducted at a testing laboratory selected by China’s regulatory agent for medical products, the National […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Publication of Technical Paper on Biophysics-Based CDA Cancer Detection Technology

December 10, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its joint technical paper on novel Cancer Differentiation Analysis (“CDA”) Technology for multi-cancer screening with multiple leading medical institutions was accepted and published online. The piece was published on Nov. 30 by the Expert Review of Molecular […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Financial, Operations Report for Latest Period

November 29, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reported its unaudited financial results and business highlights for the nine months ended Sept. 30, 2021. Financial highlights include total revenue reaching an estimated  $2.1 million, which is a 55.3% over […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Uniquely Positioned in Cancer Screening, Detection Market

November 15, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is the company behind a proprietary novel technology for early cancer screening and detection — the Cancer Differentiation Analysis (“CDA”). Powered by a database containing over 200,000 samples and cases, AnPac Bio’s CDA technology can detect and carry multifaceted information, […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Issues Update on Underwritten Public Offering of American Depositary Shares

November 11, 2021

AnPac Bio (NASDAQ: ANPC) today issued a correction to its press release dated Nov. 9, 2021, regarding the pricing of its underwritten public offering of American Depositary Shares (“ADSs”). According to the update, the original release referenced the dollar size of the offering and the number of ADSs being sold to include the exercise of […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to Begin Proposed Public Offering

November 10, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced that it is starting an underwritten public offering; the offering is comprised of ANPC’s American Depositary Shares and is subject to market and other conditions. The announcement noted that there is […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to Participate in Q4 Virtual Investor Summit

November 8, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced its participation in the Q4 Virtual Investor Summit, slated for Nov. 16–17, 2021. According to the announcement, AnPac head of investor relations, Phil Case, will present at the two-day event; AnPac’s […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging CDA Technology for Critical Early Cancer Detection

October 29, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, since 2015 has commercially proven out its concepts through the development and sale of its cancer detection technology, Cancer Differentiation Analysis (“CDA”) for early detection of pre-cancerous disease and cancer. “The company has published numerous reports of clinical study results […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) Unique Platform Offering Comprehensive Blood Test Data, New Approach to Disease Screening

October 22, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has developed the Cancer Differentiation Analysis (“CDA”) technology — a proprietary approach to detect cancerous and pre-cancerous diseases. “CDA uses the blood’s natural biophysical properties to identify cancerous environments before tumors even form. The CDA platform, in which technology is […]

News Articles

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Among Leading Biotech Companies Innovating the Field of Early Cancer Screening and Detection

October 12, 2021

Blood and genomic testing are becoming preferable means of early cancer screening and detectionLeaders innovating this niche of the medical industry include AnPac Bio, Grail, Thrive and GuardantAnPac Bio-Medical’s testing features a database of more than 200,000 commercial and research multi-cancer test samples (probably the largest multi-cancer test data base) that detect up to 26 […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Stands Distinct in World of Cancer Prevention, Treatment

October 11, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a proven early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. “AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter and multi-cancer screening. The […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Study Results Confirming Correlation Between CDA Score, Risk of Cancer

October 4, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reached a significant milestone and positive result in its general-population, cancer-risk assessment tests and subsequent follow-up study. At the end of September 2021, healthcare providers confirmed more than 2,000 cancer, precancer […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) First Half Revenue Numbers Up by 128.5%, Non-GAAP Loss Down by 18.3%

October 1, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has released it unaudited financial results for the six months ended June 30, 2021. Highlights of the report include total revenues reaching an estimated  $1.4 million, an increase of 128.5% compared to the same period in 2020; gross profit margin […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).